Congenital adrenal hyperplasia: 2026 so far

More studies tested pumps and modified-release timing strategies.

In January 2026 to September 2026, several small real-world reports linked changes in how hydrocortisone was delivered or released with lower adrenal hormone markers. One retrospective series of 13 children and adolescents with primary adrenal insufficiency, mostly CAH, reported lower ACTH (a pituitary hormone that stimulates the adrenal glands) and adrenal androgen markers after switching from tablets to continuous subcutaneous hydrocortisone infusion (CSHI, a pump that delivers hydrocortisone under the skin). Growth stayed stable, and one person stopped because of skin intolerance. Other observational cohorts and series reported that modified-release hydrocortisone (a formulation designed to release medicine over time) was accompanied by maintained biochemical control with some metabolic changes in adults, lower morning salivary markers and slower growth velocity in children, and lower adrenal markers with improved menstrual regularity in women with non-classic CAH. These reports describe what happened in specific groups, which can help guide questions to discuss with a care team, but they do not prove which approach is best or for whom.

Research covered in: January 2026, May 2026, July 2026, September 2026

More data linked CAH control with metabolic and BP outcomes.

So far in 2026, several studies linked CAH (and treatment patterns) with longer-term cardiometabolic (heart and metabolism) and blood-pressure outcomes. A large US claims analysis recorded higher rates of multiple cardiometabolic and bone conditions in people with classic CAH than matched controls, and adrenal crisis (a dangerous shortage of cortisol) was recorded in 3% of people with CAH in that dataset. In adults with classic CAH, observational studies linked modified-release hydrocortisone with improved insulin sensitivity (how well the body responds to insulin) and lower daytime blood pressure in one cohort. Another study found that visceral adiposity (fat around internal organs) and insulin resistance were more closely tied to poorer biochemical control in men. In the months covered, this keeps the focus on monitoring beyond hormone targets, including blood pressure and metabolic health over time.

Research covered in: May 2026, June 2026

Programs refined second-tier tests and context-based cutoffs.

In reports from January to September 2026, newborn screening work often aimed to reduce false positives while recognizing that screening is not perfect. Program evaluations and large cohorts reported fewer false positives when confirmatory testing used more specific steroid measurement (LC-MS/MS, a lab method that precisely measures steroid levels), when second-tier bloodspot testing was added, and when 17-OHP cutoffs were adjusted for factors like birth weight with repeat sampling when needed. One stored-sample study suggested 21-deoxycortisone performed well but still needs prospective real-time validation. At the same time, case reports and cohort observations showed CAH can still be missed, including repeated negative screens in one preterm infant later diagnosed with classic CAH, and that screening timing or logistics can delay sampling in some groups. In practical terms, an abnormal screen increasingly has clearer follow-up steps, but confirmation testing and careful clinical follow-up still matter.

Research covered in: March 2026, May 2026, June 2026, August 2026, September 2026

Multiple approaches aimed to standardize or simplify monitoring.

In the months covered, several studies looked at ways to make monitoring more consistent or practical, without showing that any one method can replace standard testing. In children, saliva hormone measurements often tracked blood levels for key markers. Automated bone-age reading (software that estimates bone maturity from an X-ray) showed lower error than individual human raters in validation cohorts. A separate study found automated bone-age reading improved adult-height prediction accuracy in girls with salt-wasting CAH. In June, dried-blood microsampling (VAMS, a device that collects a small fixed blood volume) was analytically validated for stability and measurement performance for several CAH-relevant steroids, and the authors noted that real-world clinical implementation is still needed. These findings suggest possible future ways to follow trends and reduce differences between readers or labs, but these reports did not settle how routine use should guide day-to-day decisions.

Research covered in: February 2026, May 2026, June 2026

Long-read sequencing repeatedly addressed hard-to-interpret CYP21A2 cases.

So far in 2026, several reports highlighted progress in CYP21A2 testing, especially for complex rearrangements (gene changes where pieces are moved or copied). Early in the year, long-read approaches (sequencing that reads long stretches of DNA at once) were reported to help phase variants (show which changes are on the same copy of a gene) without parental testing in many cases. Later reports described short-read and long-read sequencing workflows with high agreement to traditional methods, while also noting ongoing challenges with copy-number changes (extra or missing gene copies) and chimeras (hybrid gene segments) that may still need confirmatory testing. Case-based reports also showed that unusual inheritance or technical pitfalls, such as uniparental isodisomy (both copies of a chromosome from one parent) or sequencing dropout (a missed DNA region), can change how families interpret recurrence risk and results. This means genetic confirmation may be faster and clearer in some settings, but complicated results can still take multiple methods and expert interpretation.

Research covered in: January 2026, April 2026, June 2026, August 2026, September 2026